Gilead Sciences Buy or Sell Recommendation

Macroaxis provides Gilead Sciences Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Gilead Sciences positions. The advice algorithm takes into account all of Gilead Sciences Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Gilead Sciences buy-and-hold prospective. Please also check Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Time Horizon

Risk Tolerance

Execute Advice
Gilead Sciences Inc -- USA Stock  

USD 80.70  0.85  1.04%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Gilead Sciences Inc is 'Buy'.
For the selected time horizon Gilead Sciences Inc has a risk adjusted performance of 0.0055, jensen alpha of 0.1231, total risk alpha of 0.1945, sortino ratio of 0.0498 and treynor ratio of 0.006942
Macroaxis provides buy, hold, or sell recommendation on Gilead Sciences to complement and cross-verify current analyst consensus on Gilead Sciences Inc. Our buy or sell recommendations engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Gilead Sciences Inc is not overpriced, please check out all Gilead Sciences fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Given that Gilead Sciences Inc has Price to Earning of 22.99 times, we strongly advise you confirm Gilead Sciences Inc market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return0.003449Value At Risk4
Potential Upside3.91Standard Deviation2.50
 Return Density 

Institutional Investors

Security TypeSharesValue
Blackrock IncCommon Shares103.8 M7.4 B
Vanguard Group IncCommon Shares94.8 M6.8 B
State Street CorpCommon Shares56.5 M4 B
Capital Research Global InvestorsCommon Shares32.3 M2.3 B
Bank Of New York Mellon CorpCommon Shares30.5 M2.2 B
Fmr LlcCommon Shares24.1 M1.7 B
Parnassus InvestmentsCommon Shares19.2 M1.4 B
Susquehanna International Group LlpPut Options12.6 M901.5 M

Gilead Sciences Greeks

Alpha over DOW
Beta against DOW=0.94
Overall volatility
Information ratio =0.0524

Gilead Sciences Volatility Alert

Gilead Sciences Inc currently demonstrates below average downside deviation of 2.63. It has Information Ratio of 0.05 and Jensen Alpha of 0.12. However, we do advice investors to further question Gilead Sciences Inc expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.
 Better Than Average     
 Worse Than Average Compare Gilead Sciences to competition
FundamentalsGilead SciencesPeer Average
Return On Equity23.30 % (15.17) %
Return On Asset13.99 % (15.64) %
Profit Margin17.73 % (5.50) %
Operating Margin54.58 % (10.91) %
Current Valuation107.01 B152.14 B
Shares Outstanding1.31 B1.43 B
Shares Owned by Insiders0.69 % 6.91 %
Shares Owned by Institutions80.73 % 18.37 %
Number of Shares Shorted19.99 M3.24 M
Price to Earning22.99 times40.69 times
Price to Book5.15 times14.44 times
Price to Sales4.04 times17.81 times
Revenue26.11 B9.85 B
Gross Profit26.13 B21.75 B
EBITDA15.43 B1.41 B
Net Income4.63 B517.71 M
Cash and Equivalents36.69 B3.89 B
Cash per Share28.05 times5.17 times
Total Debt38.15 B7.36 B
Debt to Equity186.00 % 0.72 %
Current Ratio3.55 times3.30 times
Book Value Per Share15.67 times13.64 times
Cash Flow from Operations12.31 B1.25 B
Short Ratio2.14 times2.09 times
Earnings Per Share3.51 times2.30 times
Price to Earnings To Growth1.53 times1.22 times
Number of Employees8 K10.67 K
Market Capitalization105.42 B29.78 B
Total Asset1.29 B126.86 B
Retained Earnings18.15 B38.24 B
Working Capital1.08 B3.58 B
Current Asset1.18 B36.8 B


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Sale by John Milligan of 500 shares of Gilead Sciences [view details]
Risk Adjusted Performance0.0055
Market Risk Adjusted Performance0.0031
Mean Deviation1.79
Semi Deviation2.5
Downside Deviation2.63
Coefficient Of Variation72382.09
Standard Deviation2.5
Information Ratio0.0524
Jensen Alpha0.1231
Total Risk Alpha0.1945
Sortino Ratio0.0498
Treynor Ratio0.006942
Maximum Drawdown10.81
Value At Risk4.00
Potential Upside3.91
Downside Variance6.9
Semi Variance6.27
Expected Short fall1.97

Current Valuation

Gilead Sciences Current Valuation Analysis
Gilead Sciences Inc is rated # 2 in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Pharmaceuticals And Biosciences industry is currently estimated at about 353.62 Billion. Gilead Sciences totals roughly 107.01 Billion in current valuation claiming about 30% of equities listed under Pharmaceuticals And Biosciences industry.